Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 12/2016

01-12-2016 | Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections

Authors: Kyle C. Molina, Vanthida Huang

Published in: Current Infectious Disease Reports | Issue 12/2016

Login to get access

Abstract

The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance. Large surveillance programs have provided data for resistance against S. aureus for the non-glycopeptides (daptomycin, ceftaroline, tigecycline, linezolid, and tedizolid). The current published literatures suggest that worldwide resistance rates to these non-glycopeptides for serious MRSA infections are still low. Implementation of antimicrobial stewardship programs will be crucial in prevention of resistance of these antimicrobials against S. aureus.
Literature
1.
Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol. 2010;31(04):365–73.CrossRefPubMed
2.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011.
3.
Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10(8):e0136082.CrossRefPubMedPubMedCentral
4.
van Hal SJ, Fowler VG. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis. 2013;56(12):1779–88.CrossRefPubMedPubMedCentral
5.
Jacob JT, DiazGranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis. 2013;17(2):e93–e100.CrossRefPubMed
6.
Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MVN, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.CrossRefPubMedPubMedCentral
7.
Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312(15):1552–64.CrossRefPubMed
8.
Baxi SM, Clemenzi-Allen A, Gahbauer A, Deck D, Imp B, Vittinghoff E et al. Vancomycin minimum inhibitory concentration does not predict 90 day mortality, readmission or relapse in a prospective cohort of adults with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2016.
9.
Yahav D, Lador A, Paul M and Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66.
10.
Moise PA, Culshaw DL, Wong-Beringer A, Bensman J, Lamp KC, Smith WJ, et al. Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC > 1 mg/l: a multicenter evaluation. Clin Ther. 2015;38(1):16–30.CrossRefPubMed
11.
Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/l: a matched cohort study. Clin Infect Dis. 2013;56(11):1562–69.CrossRefPubMed
12.
Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40(7):1058–60.CrossRefPubMed
13.
Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50(4):1581–85.CrossRefPubMedPubMedCentral
14.
•• Stefani S, Campanile F, Santagati M, Mezzatesta ML, Cafiso V, Pacini G. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents. 2015;46(3):278–89. An overview of daptomycin resistance: the historical development, current state of resistance, as well as current research.CrossRefPubMed
15.
van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient—a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30(5):603–10.CrossRefPubMed
16.
Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, et al. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides. Eur J Clin Microbiol Infect Dis. 2016;35(4):625–31.CrossRefPubMed
17.
Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(6):2137–45.CrossRefPubMedPubMedCentral
18.
Mishra NN, Bayer AS, Weidenmaier C, Grau T, Wanner S, Stefani S, et al. Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprf and dlt operons. PLoS One. 2014;9(9):e107426.CrossRefPubMedPubMedCentral
19.
Sader HS, Jones RN. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis. 2006;43(6):798–99.CrossRefPubMed
20.
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Daptomycin activity tested against 164,457 bacterial isolates from hospitalised patients: summary of 8 years of a worldwide surveillance programme (2005–2012). Int J Antimicrob Agents. 2013;43(5):465–69. A large worldwide surveillance of 97,542 S. aureus isolates tested against daptomycin.CrossRef
21.
Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48(8):2871–75.CrossRefPubMedPubMedCentral
22.
Leonard SN, Rolek KM. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2013;68(3):644–47.CrossRefPubMed
23.
Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejuie P, Dam Q, et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med. 2013;92(2):139–49.CrossRefPubMedPubMedCentral
24.
Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, et al. B-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192–200.CrossRefPubMedPubMedCentral
25.
Yang S-J, Xiong YQ, Boyle-Vavra S, Daum R, Jones T, Bayer AS. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the “seesaw effect”). Antimicrob Agents Chemother. 2010;54(8):3161–69.CrossRefPubMedPubMedCentral
26.
Barber KE, Ireland CE, Bukavyn N, Rybak MJ. Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3(1):35–43.CrossRefPubMedPubMedCentral
27.
Dhand A, Bayer AS, Pogliano J, Yang S-J, Bolaris M, Nizet V, et al. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158–63.CrossRefPubMedPubMedCentral
28.
Davis JS, Sud A, O’Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of vancomycin and β-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173–80.CrossRefPubMed
29.
Armengol-Porta M, Tenorio-Abreu A, Bandt D, Coleman DC, Gavier-Widen D, Hotzel H, et al. In vitro activity of ceftaroline against mecC-positive MRSA isolates. J Glob Antimicrob Resist. 2016;5:3–6.CrossRefPubMed
30.
Burnett YJ, Echevarria K and Traugott KA. Ceftaroline as salvage monotherapy for persistent MRSA bacteremia: a review of current literature. Ann Pharmacother 2016.
31.
Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrobial Chemother. 2015;70(1):311–13.CrossRef
32.
Baxi SM, Chan D, Jain V. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection. 2015;43(6):751–54.CrossRefPubMedPubMedCentral
33.
Sader HS, Mendes RE, Jones RN, Flamm RK. Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States hospitals: results from the aware ceftaroline surveillance program (2012–2014). Diagn Microbiol Infect Dis 2016.
34.
Sanchez EH, Mendes RE, Sader HS, Allison GM. In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. J Antimicrob Chemother. 2016;71(6):1736–38.CrossRefPubMed
35.
Marchaim D, Pogue JM, Tzuman O, Hayakawa K, Lephart PR, Salimnia H, et al. Major variation in MICs of tigecycline in gram-negative bacilli as a function of testing method. J Clin Microbiol. 2014;52(5):1617–21.CrossRefPubMedPubMedCentral
36.
Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62 suppl 1:i17–28.CrossRefPubMed
37.
De Pascale G, Montini L, Pennisi MA, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):1–9.CrossRef
38.
Xu L, Wang YL, Du S, Chen L, Long LH, Wu Y. Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2015;61(6):323–30.CrossRef
39.
• Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from sentry antimicrobial surveillance program (2011–2013). International Journal of Antimicrobial Agents 2014. A large surveillance of 5,118 S. aureus isolates from collected from Latin American medical centers.
40.
Tärnberg M, Nilsson LE, Dowzicky MJ. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010–2013. Int J Infect Dis. 2014;49:141–48.CrossRef
41.
Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 2013;43(11–12):451–55.CrossRefPubMed
42.
Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277):207–08.CrossRefPubMed
43.
Cai JC, Hu YY, Zhou HW, Chen G-X, Zhang R. Dissemination of the same cfr-carrying plasmid among methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococcal isolates in China. Antimicrob Agents Chemother. 2015;59(6):3669–71.CrossRefPubMedPubMedCentral
44.
Thool V, Bhoosreddy G and Wadher B. Detection of resistance to linezolid in Staphylococcus aureus infecting orthopedic patients; 2012.
45.
Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013;68(1):4–11.CrossRefPubMed
46.
• Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN. Linezolid surveillance results for the United States (leader surveillance program 2014). Antimicrob Agents Chemother. 2016;60(4):2273–80. A large worldwide surveillance of 3,106 S. aureus isolates tested against lenizolid.CrossRefPubMedPubMedCentral
47.
Mendes RE, Hogan PA, Jones RN, Sader HS, Flamm RK. Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. J Antimicrob Chemother. 2016;71(7):1860–65.CrossRefPubMed
48.
Sánchez García M, De la Torre M, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303(22):2260–64.CrossRefPubMed
49.
Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (establish-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696–705.CrossRefPubMed
50.
Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the establish-1 randomized trial. JAMA. 2013;309(6):559–69.CrossRefPubMed
51.
• Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, et al. Results of the surveillance of tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015;81(2):112–18. A large surveillance of 4,449 S. aureus isolates tested against tedizolid from the United States and Europe.CrossRefPubMed
52.
Farrell D, Sader H, Mendes R, Jones R. The activity of tedizolid against gram-positive pathogens isolated from patients in medical centres in Europe, Turkey and Israel: 2014 surveillance. ECCMID 2016.
53.
Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008;52(12):4442–47.CrossRefPubMedPubMedCentral
54.
Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis. 2014;58 suppl 1:S35–42.CrossRefPubMed
Metadata
Title
Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections
Authors
Kyle C. Molina
Vanthida Huang
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 12/2016
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-016-0553-6

Other articles of this Issue 12/2016

Current Infectious Disease Reports 12/2016 Go to the issue

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Azole Resistance in Candida glabrata

Invited Commentary

Thoughts Around the Zika Virus Crisis

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)

Respiratory Infections (F Arnold, Section Editor)

Lung Ultrasound Will Soon Replace Chest Radiography in the Diagnosis of Acute Community-Acquired Pneumonia

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

Hepatic and Intra-abdominal Tuberculosis: 2016 Update

Central Nervous System Infections (K Bloch, Section Editor)

Update on the Diagnosis and Management of Neurocysticercosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits